Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

New Color On PCSK9 Inhibitors Previews Commercial Competition

This article was originally published in The Pink Sheet Daily

Executive Summary

The sponsors of the PCSK9 inhibitor class are getting lots of data boxes ticked off with the results presented at the American College of Cardiology, but it’s still largely a waiting game as investors, practitioners and patients wait for regulatory submissions and outcomes trials. New details on doses and devices preview commercial battle between Amgen’s evolocumab and Sanofi/Regeneron’s alirocumab.

Advertisement

Related Content

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

PS077035

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel